Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders





All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other


Tags
Inv. presentation
Employment agrmnt
Consulting agrmnt
Director departure
Appointed director

180 Life Sciences Corp. (KBLM) Create: Alert

All | News | Filings
Date FiledTypeDescription
10/13/2023 8-K Quarterly results
09/28/2023 8-K Quarterly results
08/15/2023 424B3 Form 424B3 - Prospectus [Rule 424(b)(3)]:
08/15/2023 424B3 Form 424B3 - Prospectus [Rule 424(b)(3)]:
08/15/2023 10-Q Quarterly Report for the period ended June 30, 2023
08/15/2023 8-K Entry into a Material Definitive Agreement, Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "A.G.P./Alliance Global Partners 590 Madison Avenue, 28th Floor 10022",
"The Holder and any assignee, by acceptance of a Warrant, acknowledge and agree that, by reason of the provisions of this paragraph, following the purchase of a portion of the Warrant Shares hereunder, the number of Warrant Shares available for purchase hereunder at any given time may be less than the amount stated on the face thereof.",
"AMENDMENT NO. 2 TO WARRANTS",
"WAIVER OF JURY TRIAL. IN ANY ACTION, SUIT, OR PROCEEDING IN ANY JURISDICTION BROUGHT BY ANY PARTY AGAINST ANY OTHER PARTY, THE PARTIES EACH KNOWINGLY AND INTENTIONALLY, TO THE GREATEST EXTENT PERMITTED BY APPLICABLE LAW, HEREBY ABSOLUTELY, UNCONDITIONALLY, IRREVOCABLY AND EXPRESSLY WAIVES FOREVER TRIAL BY JURY.",
"Investor Contact:",
"Investor Contact:"
08/14/2023 NT 10-Q Form NT 10-Q - Notification of inability to timely file Form 10-Q or 10-QSB:
08/10/2023 EFFECT Form EFFECT - Notice of Effectiveness:
08/07/2023 8-K Regulation FD Disclosure, Financial Statements and Exhibits  Interactive Data
Docs: "180 Life Sciences Announces an Agreement for a Clinical Pharmacology Study Testing a New Formulation of CBD for Enhanced Oral Uptake"
08/03/2023 8-K Regulation FD Disclosure, Financial Statements and Exhibits  Interactive Data
Docs: "180 Life Sciences Provides Update on Regulatory Approval Process in the UK and US for Dupuytren’ s Disease Treatment; Continues Consultations with the UK MHRA and Initiates a Type C Meeting Request With the US FDA"
07/31/2023 8-K Quarterly results
07/25/2023 S-1/A Form S-1/A - General form for registration of securities under the Securities Act of 1933: [Amend]
07/10/2023 8-K Quarterly results
06/16/2023 S-1 Form S-1 - General form for registration of securities under the Securities Act of 1933:
06/02/2023 4 STEINMAN LAWRENCE (Director) has filed a Form 4 on 180 Life Sciences Corp.
Txns: Bought 18,000 shares @ $1.226, valued at $22.1k
06/01/2023 4 McGovern Jr. Donald A. (Director) has filed a Form 4 on 180 Life Sciences Corp.
Txns: Bought 10,000 shares @ $1.147, valued at $11.5k
05/23/2023 DEFA14A Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material:
05/23/2023 DEF 14A Form DEF 14A - Other definitive proxy statements:
05/19/2023 4 Marrone Pamela G (Director) has filed a Form 4 on 180 Life Sciences Corp.
Txns: Bought 7,082 shares @ $1.06, valued at $7.5k
05/19/2023 4 Pamir Ozan (CFO) has filed a Form 4 on 180 Life Sciences Corp.
Txns: Bought 5,162 shares @ $1.01, valued at $5.2k
05/18/2023 4 Woody James N. (CEO) has filed a Form 4 on 180 Life Sciences Corp.
Txns: Bought 40,000 shares @ $1.03, valued at $41.2k
05/15/2023 424B3 Form 424B3 - Prospectus [Rule 424(b)(3)]:
05/15/2023 EFFECT Form EFFECT - Notice of Effectiveness:
05/12/2023 424B3 Form 424B3 - Prospectus [Rule 424(b)(3)]:
05/09/2023 PRE 14A Form PRE 14A - Other preliminary proxy statements:
05/05/2023 S-1 Form S-1 - General form for registration of securities under the Securities Act of 1933:
04/28/2023 8-K Quarterly results
04/28/2023 10-K/A Annual Report for the period ended December 31, 2022 [amend]
04/26/2023 8-K Quarterly results
04/14/2023 SC 13D/A Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend]
03/31/2023 10-K Annual Report for the period ended December 31, 2022
02/23/2023 8-K Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "180 Life Sciences Announces Allowance of Claims for a US Patent for Dupuytren’ s Disease Treatment and Application"
02/22/2023 8-K Investor presentation
Docs: "REVISED FEBRUARY 2023 180 LIFE SCIENCES CORP. PRESENTATION",
"180 Life Sciences Provides Update Regarding Anti-TNF Frozen Shoulder Trial"
01/20/2023 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "SEPARATION AND RELEASE AGREEMENT"
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy